Kwality Pharma

how big is Kwality Pharma?

As of Jun 06, Kwality Pharmaceuticals Ltd has a market capitalization of 939.00 Cr, with net sales of 370.20 Cr and a net profit of 39.85 Cr for the latest four quarters. The company has shareholder's funds of 224.21 Cr and total assets of 394.18 Cr as of the latest annual period ending in Mar'24.

Market Cap: As of Jun 06, Kwality Pharmaceuticals Ltd has a market capitalization of 939.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, which is Consolidated data, Kwality Pharmaceuticals Ltd reported Net Sales of 370.20 Cr and a Net Profit of 39.85 Cr.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The company has Shareholder's Funds amounting to 224.21 Cr and Total Assets of 394.18 Cr.

What does Kwality Pharma do?

Kwality Pharmaceuticals Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in manufacturing finished pharmaceuticals. As of March 2025, it reported net sales of 116 Cr and a net profit of 14 Cr, with a market cap of Rs 967 Cr.

Overview:<BR>Kwality Pharmaceuticals Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of finished pharmaceuticals.<BR><BR>History:<BR>Kwality Pharmaceuticals Ltd was incorporated on May 4th, 1983. The company received its first drug license in 1981 for liquid oral manufacturing. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 116 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 14 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 967 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 25.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.37<BR>- Return on Equity: 15.09%<BR>- Price to Book: 3.71<BR><BR>Contact Details:<BR>- Address: Village Nagkalan, Majitha Road Amritsar Punjab : 143601<BR>- Phone: 91-183-2774321-25<BR>- Email: cs@kwalitypharma.com<BR>- Website: http://www.kwalitypharma.com

What is the bonus history of the Kwality Pharma?

Kwality Pharma announced a 1:1 bonus issue on October 11, 2017, with a record date of October 12, 2017, allowing shareholders to receive one additional share for each share held.

Kwality Pharma has a bonus history that includes a significant event where the company announced a 1:1 bonus issue. This bonus was declared with an ex-date of October 11, 2017, and the record date was October 12, 2017. This means that shareholders on record as of the record date were entitled to receive one additional share for every share they held.

Has Kwality Pharma declared dividend?

Kwality Pharmaceuticals Ltd has declared a 6% dividend, amounting to 0.6 per share, with an ex-date of January 5, 2017. Despite this, the dividend yield is 0%, as the company has shown substantial price returns over various periods without ongoing dividend payments.

Kwality Pharmaceuticals Ltd has declared a 6% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 6%<BR>- Amount per share: 0.6<BR>- Ex-date: 05 Jan 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was 5.03%, the dividend return was 0%, resulting in a total return of 5.03%.<BR><BR>For the 1 year period, the price return was 73.5%, the dividend return was 0%, leading to a total return of 73.5%.<BR><BR>Over the 2 years period, the price return was 214.76%, the dividend return was 0%, which culminated in a total return of 214.76%.<BR><BR>In the 3 years period, the price return was 148.67%, the dividend return was 0%, resulting in a total return of 148.67%.<BR><BR>For the 4 years period, the price return was 794.74%, the dividend return was 0%, leading to a total return of 794.74%.<BR><BR>In the 5 years period, the price return was 2571.43%, the dividend return was 0%, culminating in a total return of 2571.43%.<BR><BR>Overall, while Kwality Pharmaceuticals Ltd declared a dividend, the dividend yield remains at 0%. The company has shown significant price returns over various periods, indicating strong growth despite the lack of ongoing dividend payments.

Who are the peers of the Kwality Pharma?

Kwality Pharma's peers include Bajaj Healthcare, Jagsonpal Pharma, Bliss GVS Pharma, and others. Kwality Pharma leads with a 1-year return of 134.14%, while Hester Bios has the lowest return at -35.49%.

Peers: The peers of Kwality Pharma are Bajaj Healthcare, Jagsonpal Pharma, Bliss GVS Pharma, Hester Bios, Sigachi Indust., Themis Medicare, Fermenta Biotec., Lincoln Pharma., and Bharat Parenter.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jagsonpal Pharma, while Average management risk is found at Bajaj Healthcare, Bliss GVS Pharma, Hester Bios, Sigachi Indust., Kwality Pharma, Themis Medicare, Lincoln Pharma., and Bharat Parenter. Below Average management risk is noted at Fermenta Biotec. Growth is Good at Jagsonpal Pharma, while Below Average growth is seen at Bajaj Healthcare, Bliss GVS Pharma, Hester Bios, Sigachi Indust., Kwality Pharma, Themis Medicare, Bharat Parenter, and the rest. Excellent capital structure is present at Jagsonpal Pharma, Bliss GVS Pharma, Sigachi Indust., Lincoln Pharma., and Kwality Pharma, while Average capital structure is found at Bajaj Healthcare and Bharat Parenter, and Below Average capital structure is noted at Hester Bios and Fermenta Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kwality Pharma at 134.14%, while the lowest is Hester Bios at -35.49%. Kwality Pharma's return significantly outperforms all peers. Additionally, Themis Medicare, Hester Bios, and Sigachi Indust. have negative six-month returns.

Who are in the management team of Kwality Pharma?

As of March 2022, the management team of Kwality Pharma includes Ramesh Arora (Managing Director), Ajay Arora, Geeta Arora, Anju Arora, Aditya Arora (CFO), and several independent directors, along with Gurpreet Kaur (Company Secretary). This team oversees various operational and governance aspects of the company.

As of March 2022, the management team of Kwality Pharma includes the following individuals:<BR><BR>1. Ramesh Arora - Managing Director<BR>2. Ajay Arora - Whole-time Director<BR>3. Geeta Arora - Whole-time Director<BR>4. Anju Arora - Whole-time Director<BR>5. Aditya Arora - Whole Time Director & CFO<BR>6. Ravi Shanker Singh - Independent Director<BR>7. Pankaj Takkar - Independent Director<BR>8. Kiran Kumar Verma - Independent Director<BR>9. Kartik Kapur - Independent Director<BR>10. Gurpreet Kaur - Company Secretary & Compliance Officer<BR>11. Sachin Seth - Director<BR><BR>This diverse team includes various directors and officers responsible for different aspects of the company's operations and governance.

Who are the top shareholders of the Kwality Pharma?

The top shareholders of Kwality Pharma are Ramesh Arora, holding 26.01%, and Deepak Bansal, with 10.63%. Individual investors collectively own 33.39%, while there are no mutual funds or foreign institutional investors involved.

The top shareholders of Kwality Pharma include Ramesh Arora, who is the promoter with the highest holding at 26.01%. The highest public shareholder is Deepak Bansal, holding 10.63%. Additionally, individual investors collectively hold 33.39% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

When is the next results date for Kwality Pharma?

The next results date for Kwality Pharma is 11 August 2025.

The next results date for Kwality Pharma is scheduled for 11 August 2025.

Is Kwality Pharma overvalued or undervalued?

As of November 14, 2025, Kwality Pharma is considered undervalued with a favorable valuation grade, reflected in its PE ratio of 20.24 and strong recent stock performance, especially compared to more expensive peers like Sun Pharma and Divi's Lab.

As of 14 November 2025, the valuation grade for Kwality Pharma has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued based on its key financial ratios, including a PE ratio of 20.24, an EV to EBITDA of 11.51, and a PEG ratio of 0.45, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Kwality Pharma's valuation appears favorable; for instance, Sun Pharma has a PE ratio of 36.49, while Divi's Lab shows a significantly higher PE of 69.65, both categorizing them as expensive. Additionally, Cipla, which is also rated attractive, has a PE ratio of 22.72, further highlighting Kwality Pharma's relative value. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 11.37% compared to the Sensex's 1.62%, reinforcing the argument for its undervaluation.

How has been the historical performance of Kwality Pharma?

Kwality Pharma's historical performance shows fluctuating trends, with net sales increasing from 251.03 Cr in Mar'23 to 370.20 Cr in Mar'25, despite a peak of 456.19 Cr in Mar'22. While operating profit and net income improved, the volatility in sales and profit margins indicates a need for strategic stability.

Answer:<BR>The historical performance of Kwality Pharma shows a fluctuating trend in its financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Kwality Pharma's net sales increased from 251.03 Cr in Mar'23 to 370.20 Cr in Mar'25, reflecting a significant growth trajectory. However, this growth follows a peak in Mar'22 at 456.19 Cr, indicating volatility in sales performance. Total operating income mirrored this trend, rising to 370.20 Cr in Mar'25 from 251.03 Cr in Mar'23, while total expenditure also increased to 289.81 Cr in Mar'25 from 190.89 Cr in Mar'23. Operating profit, excluding other income, improved to 80.39 Cr in Mar'25, up from 60.14 Cr in Mar'23, although it was significantly higher at 171.67 Cr in Mar'22. Profit before tax also saw an increase to 54.14 Cr in Mar'25 from 25.57 Cr in Mar'23, while profit after tax rose to 39.80 Cr in Mar'25 from 19.28 Cr in Mar'23. The company's total assets grew to 445.66 Cr in Mar'25 from 353.63 Cr in Mar'23, alongside total liabilities which increased to 445.66 Cr from 394.18 Cr in the same period. Cash flow from operating activities improved to 52.00 Cr in Mar'25 from 41.00 Cr in Mar'23, contributing to a net cash inflow of 9.00 Cr in Mar'25, compared to an outflow of 6.00 Cr in Mar'23. Overall, while Kwality Pharma has shown growth in several key areas, the fluctuations in sales and profit margins suggest a need for strategic stability moving forward.

Is Kwality Pharma technically bullish or bearish?

As of December 3, 2025, Kwality Pharma's technical trend is bearish with moderate strength, driven by bearish MACD and moving averages, despite a mildly bullish indication from Bollinger Bands on the monthly timeframe.

As of 3 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Kwality Pharma is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on the weekly. The Bollinger Bands indicate a mildly bullish trend on the monthly, but overall, the prevailing bearish signals dominate the analysis.

Are Kwality Pharmaceuticals Ltd latest results good or bad?

Kwality Pharmaceuticals Ltd's latest results are positive, with a net profit of ₹16.01 crores and revenue growth of 46.24% year-on-year. However, while the company shows strong performance, investors should be cautious about the sustainability of such high growth rates in a competitive market.

Kwality Pharmaceuticals Ltd's latest results can be considered quite positive. In the quarter ending December 2025, the company reported a significant net profit of ₹16.01 crores, which marks an impressive year-on-year growth of 87.69%. Additionally, revenue grew by 46.24% compared to the same quarter last year, reaching ₹123.44 crores. This growth reflects strong demand for their pharmaceutical products and indicates that the company is maintaining robust momentum in its operations.<BR><BR>The operating margin also improved to 24.26%, up from 20.73% in the previous year, showcasing effective cost management and operational efficiencies. Furthermore, the return on equity (ROE) stands at a solid 16.91%, highlighting effective capital utilization.<BR><BR>While the results are strong, there are underlying concerns regarding the sustainability of such high growth rates, especially in a competitive pharmaceutical market. Investors are advised to consider these factors when evaluating the company's future prospects. Overall, the latest financial performance suggests that Kwality Pharmaceuticals is currently in a strong position, but caution regarding future growth sustainability is warranted.

Should I buy, sell or hold Kwality Pharmaceuticals Ltd?

Why is Kwality Pharmaceuticals Ltd falling/rising?

As of 16-Mar, Kwality Pharmaceuticals Ltd's stock price is Rs 1,579.00, down 0.13%. Despite a recent slight decline, the stock has shown strong performance over time, significantly outperforming the Sensex, with a year-to-date increase of 42.46%.

As of 16-Mar, Kwality Pharmaceuticals Ltd's stock price is currently at Rs 1,579.00, reflecting a slight decrease of Rs 2.1 or 0.13%. Despite this minor decline, the stock has shown strong performance over various time frames, outperforming the benchmark Sensex significantly. Over the past week, the stock has risen by 5.76%, while the Sensex has fallen by 2.66%. In the last month, it has increased by 11.10% compared to a 9.34% drop in the Sensex. Year-to-date, the stock has surged by 42.46%, contrasting with the Sensex's decline of 11.40%. <BR><BR>However, it is important to note that the stock has been experiencing a consecutive fall for the last three days, with a total decline of 5.05% during this period. The stock reached an intraday high of Rs 1,635.55, indicating some volatility, as it also touched a low of Rs 1,532.65. The trading volume has shown an increase, with delivery volume rising by 3.01% against the 5-day average, suggesting that investor interest remains strong despite the recent price drop. <BR><BR>Overall, while the stock is currently experiencing a slight decline, its strong performance over longer periods and increased investor participation indicate a generally positive outlook.

Which are the latest news on Kwality Pharma?